Please login to the form below

Not currently logged in
Email:
Password:

diffuse large B-cell lymphoma

This page shows the latest diffuse large B-cell lymphoma news and features for those working in and with pharma, biotech and healthcare.

Gracell reports impressive data with one-day CAR-T for leukaemia

Gracell reports impressive data with one-day CAR-T for leukaemia

Kymriah is approved for B-ALL as well as diffuse large B-cell lymphoma (DLBCL) – a form of non-Hodgkin’s lymphoma – and made just over $100m in sales in the ... Meanwhile, Gilead reported $216m in first-half sales from DLBCL and another NHL variant

Latest news

  • Novartis’ CAR-T Kymriah scores SMC approval Novartis’ CAR-T Kymriah scores SMC approval

    The SMC approved the CAR-T therapy for use in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who have not responded to two or more prior ... From the testimonies given by patient groups and clinicians through our PACE

  • Imbruvica gains expanded use in Europe Imbruvica gains expanded use in Europe

    It is also approved for use in mantle cell lymphoma (MCL) for the treatment of adult patients who have relapsed or refractory MCL. ... B-cell lymphoma.

  • Triplet approvals for myeloma boost Celgene in Q2 Triplet approvals for myeloma boost Celgene in Q2

    Abraxane is enjoying a sales surge thanks to its use in combination with cancer immunotherapies in indications like non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC), according ... CAR-T therapy liso-cel (lisocabtagene maraleucel

  • J&J takes option on Genmab follow-up to Darzalex J&J takes option on Genmab follow-up to Darzalex

    Johnson &Johnson’s longstanding alliance with Genmab has already produced one blockbuster drug for lymphoma – Darzalex – and it is now eyeing a follow-up candidate. ... Under the terms of the deal Genmab will develop HexaBody-CD38 for multiple

  • Roche’s Polivy gets FDA okay for lymphoma chemo-immunotherapy Roche’s Polivy gets FDA okay for lymphoma chemo-immunotherapy

    First-in-class antibody drug conjugate. The FDA has approved Roche’s Polivy as part of the first chemo-immunotherapy combination for a B-cell lymphoma. ... The antibody-drug conjugate has been cleared for use alongside the chemotherapy bendamustine and

More from news
Approximately 1 fully matching, plus 73 partially matching documents found.

Latest Intelligence

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    The phase 2 L-MIND study in diffuse large B-cell lymphoma (DLBCL) showed the combination of tafasitamab with Celgene’s Revlimid (lenalidomide) had an overall response rate of 60%, with ... Nevertheless, European biotech has reason to be optimistic

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    13. SORAYA BEKKALI. Gene therapy pioneer. Cell and gene therapy is definitely the most exciting development in biopharma research, promising breakthroughs and even cures for previously untreatable diseases. ... It has brought to market not one but two

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... Celgene and Juno hope to crash the party

  • Deal Watch January 2018

    pivotal trial for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL).  According to Celgene's press release, regulatory approval for JCAR017 in the US is anticipated in 2019 with ... DLBCL = diffuse large B-cell lymphoma. BTK = Bruton's

  • Pharma deals in April 2015 Pharma deals in April 2015

    MEDI4736 is an immune checkpoint inhibitor which is targeted against programmed cell death (PD-L1). ... its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...
Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...

Infographics